Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Avastin (Bevacizumab Injection) in healthy Chinese male subjects.
Metastatic Colorectal Cancer|Non Small Cell Lung Cancer Metastatic|Non Small Cell Lung Cancer Recurrent
DRUG: LY01008|DRUG: Avastin
Area under the plasma concentration-time curve from time zero to the last measurable concentration（AUC0-t）, From baseline to Day 99|Area under the plasma concentration-time curve from time zero to infinity（AUC0-∞）, From baseline to Day 99|Maximum (peak) plasma concentration（Cmax）, From baseline to Day 99|Chloride（CL）, From baseline to Day 99|Terminal elimination half-life（t1/2）, From baseline to Day 99|Apparent volume of distribution（Vd）, From baseline to Day 99
Adverse Events(AEs), From baseline to Day 99|Vital signs, From baseline to Day 99|Physical examinations, From baseline to Day 99|Clinical laboratory tests, From baseline to Day 99|12-lead ECGs, From baseline to Day 99|Positive rate of serum anti-drug antibody (ADA), From baseline to Day 99|Positive rate of neutralizing antibody (NAb), From baseline to Day 99
This is a randomized, double-blind, single-dose, parallel-group study comparing pharmacokinetic characteristics, safety , tolerability and immunogenicity of LY01008 (Recombinant Humanized Anti-Human Vascular Endothelial Growth Factor Monoclonal Antibody Injection) and Avastin (Bevacizumab Injection) in healthy Chinese male subjects.